{"id":"vestronidase-alfa-vjbk","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Infusion site extravasation","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Infusion site swelling","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral swelling","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Febrile convulsion","drugRate":"8.3%","severity":"serious"}]},"status":"approved","trials":["NCT04532047","NCT03604835","NCT02432144","NCT02230566","NCT01856218","NCT02418455","NCT02097251","NCT03775174"],"aliases":[],"company":"ULTRAGENYX PHARM INC","patents":[],"pricing":[],"allNames":"mepsevii","offLabel":[],"timeline":[],"brandName":"MEPSEVII","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"VESTRONIDASE ALFA-VJBK","indications":{"approved":[{"name":"Mucopolysaccharidosis, MPS-VII","diseaseId":"mucopolysaccharidosis-mps-vii","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"ULTRAGENYX PHARM INC","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04532047","phase":"Phase 1","title":"PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)","status":"RECRUITING","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":10,"indication":"MPS I, MPS II","completionDate":"2032-07-31"},{"nctId":"NCT03604835","phase":"N/A","title":"Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)","status":"RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":false,"enrollment":50,"indication":"Mucopolysaccharidosis VII, MPS VII","completionDate":"2033-05"},{"nctId":"NCT02432144","phase":"Phase 3","title":"A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":true,"enrollment":12,"indication":"Sly Syndrome, MPS VII","completionDate":"2019-01-14"},{"nctId":"NCT02230566","phase":"Phase 3","title":"A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":true,"enrollment":12,"indication":"MPS 7, Sly Syndrome","completionDate":"2016-05"},{"nctId":"NCT01856218","phase":"Phase 1","title":"An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":false,"enrollment":3,"indication":"Mucopolysaccharidosis Type 7","completionDate":"2016-07"},{"nctId":"NCT02418455","phase":"Phase 2","title":"An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":false,"enrollment":8,"indication":"Sly Syndrome, MPS VII","completionDate":"2019-03-26"},{"nctId":"NCT02097251","phase":"N/A","title":"An Open-Label Treatment Protocol With UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy for an Advanced Stage Mucopolysaccharidosis Type 7 (MPS 7) Patient","status":"NO_LONGER_AVAILABLE","sponsor":"Joyce Fox","isPivotal":false,"enrollment":0,"indication":"Mucopolysaccharidosis Type 7","completionDate":""},{"nctId":"NCT03775174","phase":"N/A","title":"","status":"AVAILABLE","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":false,"enrollment":0,"indication":"MPS VII, Mucopolysaccharidosis VII","completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"INJECTION","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"ULTRAGENYX PHARM INC","companyId":"ultragenyx-pharm-inc","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Mepsevii is a hydrolytic enzyme used to treat Mucopolysaccharidosis VII, also known as Sly Syndrome. It works by hydrolyzing glycosaminoglycans, a type of molecular target.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2018-08-23T00:00:00.000Z","mah":"Ultragenyx Germany GmbH","brand_name_local":"Mepsevii","application_number":"EMEA/H/C/004438"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}